Drug Profile
NHM CT 007
Alternative Names: NHM-CT-007Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Chem Tech Research
- Developer DelSiTech
- Class Antineoplastics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Cancer in South Korea (Parenteral, Controlled release)
- 18 Dec 2017 C-Tri inlicensed DelSiTech's Silica Matrix technology for the development of NHM-CT-007 for Cancer
- 18 Dec 2017 Early research in Cancer in South Korea (Parenteral)